In a listing that raised nearly $130M, Suzhou-based Ascentage became the 1st biotech to initially list on the Hong Kong stock exchange’s biotech chapter and subsequently conduct a NASDAQ offering. h/t @biobonanos.bsky.social
Comments
Log in with your Bluesky account to leave a comment
Comments